Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2i in Diabetic Renal Transplant Patients
NCT06731231Phase 2Active, not recruiting
- Sponsor
- Ain Shams University
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dapagliflozin in post-transplant diabetes mellitus (PTDM) (2 arms), sponsored by Ain Shams University. Primary endpoints: Glycemic control by SGLT2i at 6 months and SGLT2i-related side effects at 6 months. Started Mar 2024; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
post-transplant diabetes mellitus (PTDM)
Beyond the preview
Go deeper on NCT06731231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731231.